AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma

PURPOSE: Patients with indolent non-Hodgkin lymphoma typically respond well to first-line immunochemotherapy. At relapse, single-agent rituximab is commonly administered. Data suggest the immunomodulatory agent lenalidomide could increase the activity of rituximab. METHODS: A phase III, multicenter,...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Clin Oncol
Egile Nagusiak: Leonard, John P., Trneny, Marek, Izutsu, Koji, Fowler, Nathan H., Hong, Xiaonan, Zhu, Jun, Zhang, Huilai, Offner, Fritz, Scheliga, Adriana, Nowakowski, Grzegorz S., Pinto, Antonio, Re, Francesca, Fogliatto, Laura Maria, Scheinberg, Phillip, Flinn, Ian W., Moreira, Claudia, Cabeçadas, José, Liu, David, Kalambakas, Stacey, Fustier, Pierre, Wu, Chengqing, Gribben, John G.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Clinical Oncology 2019
Gaiak:
ORIGINAL REPORTS
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7035866/
https://ncbi.nlm.nih.gov/pubmed/30897038
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.00010
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak